Business Context and Reporting Period
This Form 8-K Current Report was filed by MRI Interventions, Inc. (not Clearpoint Neuro, Inc.) on December 24, 2014. The report details the completion of a private placement financing transaction previously announced by the Company.
Key Financial Metrics
- Gross Proceeds: Approximately $10.2 million received from the sale of securities.
- Transaction Costs: Approximately $0.7 million in placement agents' fees and estimated offering expenses.
- Securities Issued: Approximately 15.8 million shares of common stock.
- Warrants Issued: Approximately 6.3 million Investor Warrants and 1.1 million Placement Agent Warrants.
- Warrant Exercise Price: $0.858 per share.
- Warrant Expiration: December 24, 2019.
Material Changes
The primary material change is the increase in equity capital and potential dilution resulting from the Financing Transaction. The Company sold unregistered equity securities to accredited investors under Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D. This transaction significantly alters the Company's capital structure compared to the pre-closing period.
Outlook, Risks, and Contingencies
- Registration Rights: The Company entered into a Registration Rights Agreement requiring the filing of a registration statement within 30 calendar days of the closing (by January 23, 2015) to allow investors to resell shares.
- Liquidated Damages: The Company faces potential liquidated damages if the registration statement is not filed by the deadline, not declared effective by the 75th day (or 120th day if reviewed by the SEC), or if effectiveness is not maintained.
- Warrant Features: Investor Warrants include a cashless exercise feature and a redemption provision if the stock price exceeds twice the exercise price ($1.716) for 20 consecutive trading days. Placement Agent Warrants do not include the redemption provision.
Investor Verification Checklist
- Verify the net cash proceeds after deducting the $0.7 million in fees and other expenses.
- Confirm the filing date and status of the required Registration Statement to avoid liquidated damages.
- Review the full text of the Securities Purchase Agreement and Warrant forms (Exhibits 10.1, 10.2, and 4.1) for specific adjustment mechanisms and dilution impacts.
- Assess the impact of the 15.8 million new shares and 7.4 million total warrants on existing shareholder ownership percentages.